Regorafenib is a multikinase inhibitor with activity against KIT, RET, RAF1, BRAF, PDGFR, FGFR EGFR1–3 and TEK, approved in 2013 for the treatment of patients with locally advanced, unresectable, or metastatic GIST previously treated with imatinib and sunitinib. This evidence concerns the gene RET and gastrointestinal stromal tumor.